文献速递神经肿瘤

MEF2C沉默下调NF2与E-cadherin并增强Erastin诱导的脑膜瘤铁死亡

MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
PubMed 文献 · Neuro Oncol · 2021-01-01

该研究探讨铁死亡与NF2状态及E-cadherin表达在脑膜瘤中的关系。在35例脑膜瘤(10例NF2缺失,25例NF2野生型)中检测铁死亡调节因子与NF2突变状态的关系,并在IOMM-Lee、CH157及患者来源脑膜瘤细胞模型及异种移植小鼠模型中验证。结果显示NF2失活和低E-cadherin使脑膜瘤对Erastin诱导的铁死亡敏感,MEF2C驱动NF2和CDH1表达,MEF2C沉默增强Erastin的抗脑膜瘤效果。

要点

  • NF2失活和低E-cadherin使脑膜瘤对Erastin诱导的铁死亡敏感。
  • MEF2C驱动NF2和E-cadherin表达,沉默MEF2C增强Erastin诱导的铁死亡。
  • MEF2C可能是脑膜瘤铁死亡诱导治疗的新分子靶点。

核心结论

  • NF2缺失和低E-cadherin使脑膜瘤对铁死亡敏感。
  • MEF2C可能成为脑膜瘤铁死亡诱导治疗的新分子靶点。

研究设计与样本

  • 在35例脑膜瘤(10例NF2缺失,25例NF2野生型)中检测铁死亡调节因子表达与NF2突变状态的关系。
  • 在IOMM-Lee、CH157及患者来源脑膜瘤细胞模型中通过LDH释放、脂质过氧化和western blot检测NF2和E-cadherin对铁死亡的影响。
  • 用荧光素酶报告基因和染色质免疫沉淀实验评估MEF2C驱动NF2和CDH1表达的能力。
  • 在异种移植小鼠模型中测试Erastin诱导铁死亡的疗效。

主要发现

  • NF2失活的脑膜瘤细胞对Erastin诱导的铁死亡敏感。
  • 高密度生长的脑膜瘤细胞增加E-cadherin表达,抑制Erastin诱导的铁死亡。
  • 维持NF2和E-cadherin抑制铁死亡相关脂质过氧化和脑膜瘤细胞死亡。
  • MEF2C驱动NF2和E-cadherin两者表达。
  • MEF2C沉默增强Erastin诱导的脑膜瘤细胞铁死亡和脂质过氧化,该效应被强制表达NF2或E-cadherin限制。

临床怎么用

  • 对NF2缺失或低E-cadherin的脑膜瘤,可考虑铁死亡诱导治疗策略。
  • MEF2C可作为脑膜瘤铁死亡诱导治疗的潜在分子靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ferroptosis, a programmed cell death characterized by lipid peroxidation, is implicated in various diseases including cancer. Although cell density-dependent E-cadherin and Merlin/Neurofibromin (NF2) loss can modulate ferroptosis, the role of ferroptosis and its potential link to NF2 status and E-cadherin expression in meningioma remain unknown. METHODS: Relationship between ferroptosis modulators expression and NF2 mutational status was examined in 35 meningiomas (10 NF2 loss and 25 NF2 wild type). The impact of NF2 and E-cadherin on ferroptosis were examined by lactate dehydrogenase (LDH) release, lipid peroxidation, and western blot assays in IOMM-Lee, CH157, and patient-derived meningioma cell models. Luciferase reporter and chromatin immunoprecipitation assays were used to assess the ability of MEF2C (myocyte enhancer factor 2C) to drive expression of NF2 and CDH1 (E-cadherin). Therapeutic efficacy of Erastin-induced ferroptosis was tested in xenograft mouse models. RESULTS: Meningioma cells with NF2 inactivation were susceptible to Erastin-induced ferroptosis. Meningioma cells grown at higher density increased expression of E-cadherin, which suppressed Erastin-induced ferroptosis. Maintaining NF2 and E-cadherin inhibited ferroptosis-related lipid peroxidation and meningioma cell death. MEF2C was found to drive the expression of both NF2 and E-cadherin. MEF2C silencing enhanced Erastin-induced ferroptotic meningioma cell death and lipid peroxidation levels in vitro, which was limited by forced expression of MEF2C targets, NF2 and E-cadherin. In vivo, anti-meningioma effect of Erastin was augmented by MEF2C knockdown and was counteracted by NF2 or E-cadherin. CONCLUSIONS: NF2 loss and low E-cadherin create susceptibility to ferroptosis in meningioma. MEF2C could be a new molecular target in ferroptosis-inducing therapies for meningioma.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bao Z, Hua L, Ye Y, et al. MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma. Neuro Oncol. 2021. PMID: 33984142. doi:10.1093/neuonc/noab114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。